Graznya Kwapiszewska, Christopher Rhodes, Marlene Rabinovitch, Catherine Simpson, Paul Hassoun, Kenzo Ichimura, Marc Humbert, Edda Spiekerkoetter
Medical University Graz. Imperial College London. Stanford University. Johns Hopkins University. Hopital Bicetre.
Austria, United Kingdom, United States and France
American Journal of Respiratory Cell and Molecular Biology
Am J Respir Cell Mol Biol 2025;
DOI: 10.1165/rcmb.2024-0519PS
Abstract
The rapid advancement of next-generation omics platforms, bioinformatic data analysis, and novel imaging techniques is transforming biomedical research, especially in pulmonary hypertension. These cutting-edge tools generate vast data, leading to innovative therapeutic and diagnostic possibilities, such as personalized medicine and patient-specific risk stratification. However, while embracing new technologies, it is crucial to integrate decades of hypothesis-driven research with emerging discovery platforms to avoid redundant efforts and enhance scientific progress. At the 2024 American Thoracic Society (ATS) conference, senior and junior investigators in vascular biology, pulmonary hypertension, and right heart failure engaged in pro/con debates on research paradigms. These discussions explored how evolving disease frameworks fit within the context of traditional research, emphasizing the balance between newer multi-omics approaches and classical hypothesis-driven science. Three key objectives were addressed: (1) integrating unbiased analytic methods with traditional frameworks, (2) interpreting new multi-omics findings within known pathobiological pathways, and (3) reviewing modern imaging methods for the right ventricle to improve disease understanding. While omics approaches offer a broad, integrative view and support personalized medicine, they present challenges, such as managing large datasets and ensuring effective clinical translation. Conversely, traditional reductionist approaches, focusing on known genetic alterations and signaling pathways, have led to significant breakthroughs, including the development of current therapies. Combining both approaches holds great potential to drive future discoveries and develop more effective treatments for pulmonary hypertension, a goal that can only be achieved through coordinated, transdisciplinary teams of investigators with diverse skillsets and knowledge working together to advance the field.
Category
Other
Age Focus: Pediatric Pulmonary Vascular Disease or Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No